Nicotinic systems in central nervous systems disease: Degenerative disorders and beyond

Pharmaceutica Acta Helvetiae

Volumn 74, Issue 2-3, 2000, Pages 91-101

  Newhouse, Paul A ^a   Kelton, Megan ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Alzheimer's disease; Analgesia; Nicotine; Nicotinic agonists; Parkinson's disease; Schizophrenia; Tourette's syndrome

Indexed keywords

3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE FUMARATE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; EPIBATIDINE; MECAMYLAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; ANALGESIA; ATTENTION DEFICIT DISORDER; BEHAVIOR; BINDING AFFINITY; BRAIN BLOOD FLOW; CENTRAL NERVOUS SYSTEM; COGNITION; CONFERENCE PAPER; DEGENERATIVE DISEASE; DEPRESSION; DRUG RECEPTOR BINDING; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HUMAN; LEARNING; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RECEPTOR DENSITY; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CHOLINERGIC AGENTS; HUMANS; NEURODEGENERATIVE DISEASES; RECEPTORS, NICOTINIC;

EID: 0034025765     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00047-3     Document Type: Conference Paper

References (117)

1. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry. 32:1992;607-616.
2. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry. 150:1993;1856-1861.
3. Arendash G.W., Sengstock G.J., Sanberg P.R., Kem W.R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674:1995;252-259.
4. Arneric S.P. Basal forebrain neurons modulate cortical cerebral blood flow: increases by nicotinic cholinergic mechanisms. J. Cereb. Blood Flow Metab. 9:1989;S502. Suppl. 1.
5. Arneric S.P., Anderson D., Bannon A., Briggs A.W., Clark A., Brion J.et al. Preclinical pharmacology of ABT-418: a prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drug Rev. 1:1995;1-26.
6. Aubert I., Araujo D.M., Cécyre D., Robitaille Y., Gauthier S., Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58:1992;529-541.
7. Balfour D.J., Fagerstrom K.O. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol. Ther. 72:1996;51-81.
8. Bannon A.W., Decker M.W., Holladay M.W. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 2:1998;77-81.
9. Barkley R.A. Attention-deficit/hyperactivity disorder, self-regulation, and time: towards a more comprehensive theory. J. Dev. Behav. Pediatr. 18:1997;271-279.
10. Baron J.A. Cigarette smoking and Parkinson's disease. Neurology. 36:1986;1490-1496.
11. Baron, J.A., 1994. Epidemiology of smoking and Parkinson's disease. In: Clarke, Quik, Thurau, Adlkofer (Eds.), Effects of Nicotine on Biological Systems II, Birkhäuser, Boston, S42.
12. Baumann R.J., Jameson H.D., McKean H.D., Maack D.G., Weisberg L.M. Cigarette smoking and Parkinson's disease: 1. Comparison of cases with matched neighbors. Neurology. 30:1980;839-843.
13. Bickford-Wimer P.C., Nagamoto H., Johnson R., Adler L.E., Egan M., Rose G.M.et al. Auditory sensory gating in hippocampal neurons: a model system in the rat. Biol. Psychiatry. 27:1990;183-192.
14. Borlongan C.V., Shytle R.D., Ross S.D., Shimizu T., Freeman T.B., Cahill D.W. Nicotinic protects against systemic kainic acid-induced excitotoxic effects. Exp. Neurol. 136:1995;261-265.
15. Brioni J.D., O'Neill A.B., Kim D.J.B., Buckley M.J., Decker M.W., Arneric S.P. Anxiolytic-like effects of the novel cholinergic channel activator ABT 418. J. Pharmacol. Exp. Ther. 271:1994;353-361.
16. Brioni J.D., Decker M.W., Sullivan J.P., Arneric S.P. The pharmacology of (-)-nicotine and novel cholinergic modulators. Adv. Pharmacol. 37:1997;153-214.
17. Buccafusco J.J., Jackson W.J., Terry A.V. Jr., Marsh K.C., Decker M.W., Arneric S.P. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology. 120:1995;256-266.
18. Caggiula A.R., Epstein L.H., Perkins K.A., Saylor S. Different methods of assessing nicotine-induced antinociception may engage different neural mechanisms. Psychopharmacology. 122:1995;301-306.
19. Carlson N.G., Bacchi A., Rogers S.W., Gahring L.C. Nicotine blocks TNF-alpha-mediated neuroprotection to NMDA by an alpha-bungarotoxin-sensitive pathway. Neurobiology. 35:1998;29-36.
20. Conners C.K., Levin E.D., Sparrow E., Hinton S., Ernhardt D., Meck W.H., Rose J.E., March J. Nicotine and attention deficit in adult ADHD. Psychopharmacol. Bull. 32:1996;67-73.
21. Dalack G., Healy D., Meador-Woodruff J. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am. J. Psychiatry. 155:1998;1490-1501.
22. Donnelly-Roberts D.L., Xue I.C., Arneric S.P., Sullivan J.P. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res. 719:1996;36-44.
23. Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E.et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotine acetylcholine receptors: I. In vitro characterization. J. Pharmacol. Exp. Ther. 285:1998;777-786.
24. Dursan S.M., Revely M.A., Bird R., Stirton F. Long lasting improvement of Tourette's syndrome with transdermal nicotine. Lancet. 344:1994;1577.
25. Emerich D.F., Zanol M.D., Norman A.B., McConville B.J., Sanberg P.R., Fiore M.C.et al. Nicotine potentiates haloperidol-induced catalepsy and hyperactivity. Pharmacol. Biochem. Behav. 38:1991;875-880.
26. Fagerström K.O., Pomerleau O., Giordani B., Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology. 116:1994;117-119.
27. Fiore, M.C., Bailey, W.C., Cohen, S.J. et al., 1996. Smoking cessation. Clinical Practice Guideline No 18. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 96-0692.
28. 3H ]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal J. Neurochem. 47:1986;1948-1954.
29. Foulds J., Stapleton J.A., Bell N., Swedenham J., Jarvis M.J., Russell M.A. Mood and physiological effects of subcutaneous nicotine in smokers and never-smokers. Drug Alcohol Depend. 44:1997;105-115.
30. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R.et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736.
31. Freedman R., Wetmore C., Stromberg I., Leonaard S., Olson L. α-Bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effects on growth-factor expression. J. Neurosci. 13:1993;1965-1975.
32. Freedman R., Adler L.E., Bickford P., Byerley W., Coon M., Cullum C.N.et al. Schizophrenia and nicotine receptors. Harvard Rev. Psychiatry. 2:1994;179-192.
33. Freedman R., Coon H., Myles-Worsley M., Orr-urteger A., Olincy A., Davis A.et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. 94:1997;587-592.
34. Fuld P., Katzman R., Davies P., Terry R.D. Intrusions as a sign of Alzheimer dementia: chemical and pathological verification. Ann. Neurol. 11:1982;155-159.
35. Gilbert D.G. Paradoxical tranquilizing and emotion-reducing effect of nicotine. Psychol. Bull. 86:1979;643-661.
36. Gitelman D.R., Prohovnik I. Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol. Aging. 13:1992;313-318.
37. Glassman A.H., Helzer J.E., Covey L.S., Cuttler L.B., Stetner F., Tipp J.E.et al. Smoking, smoking cessation, and major depression. JAMA. 264:1990;1546-1549.
38. Gray J., Rajan A.S., Radcliffe K.A., Yakehiro M., Dani J.A. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature. 383:1996;713-716.
39. Hughes, J.R., 1998. Dependence on the abuse of nicotine replacement medications: an update. In: Benowitz, N. (Ed.), Nicotine Safety and Toxicity. Oxford, New York, pp. 147-160.
40. Iaboni F., Douglas V.I., Baker A.G. Effects of reward and response costs on inhibition in ADHD children. J. Abnorm. Psychol. 104(1):1995;232-240.
41. Itoh A., Nitta A., Nadai M., Nishimura K., Hirose M., Hasegawa T.et al. Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats. J. Neurochem. 66:1996;1113-1117.
42. James J.R., Nordberg A. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav. Genet. 25:1995;149-159.
43. Jamner L.D., Girdler S.S., Shapiro D., Jarvik M.E. Pain inhibition, nicotine and gender. Exp. Clin. Psychopharmacol. 6:1998;96-106.
44. Jones G.M.M., Sahakian B.J., Levy R., Warburton D.M., Gray J.A. Effects of acute subcutaneous nicotine on attention, information processing and short term memory in Alzheimer's disease. Psychopharmacology. 108:1992;485-494.
45. Kaneko S., Maeda T., Kume T., Kochiyama H., Akaike A., Shimohama S.et al. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha 7-neuronal receptors and neuronal CNS receptors. Brain Res. 765:1997;135-140.
46. Katayama, S., Hirata, K., Tanaka, H. et al., 1995. Efficacy of transdermal nicotine in dementia: a study using event-related potentials and a middle latency response. In: Brain Imaging of Nicotine and Tobacco Smoking. NPP Books, Ann Arbor, pp. 289-302.
47. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H.et al. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann. Neurol. 42:1997;159-163.
48. Kirch, D.G., 1999. Nicotine and major mental disorders. In: Piasecki, M., Newhouse, P. (Eds.), Nicotine in Psychiatry: Emerging Trends in Psychopathology and Novel Therapeutics. American Psychiatric Press, Washington, in press.
49. Lee P.N. Smoking and Alzheimer's disease: a review of the epidemiologic evidence. Neuroepidemiology. 13:1994;131-144.
50. Lena C., Changeux J.P. Allosteric nicotinic receptors, human pathologies. J. Physiology (Paris). 92:1998;63-74.
51. Levin E.D., Conners C.K., Sparrow E., Hinton S.C., Erhardt D., Meck W.M.et al. Nicotine effects on adults with attention deficit/hyperactivity disorder. Psychopharmacology. 123:1996;55-63.
52. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 15:1996;429-436.
53. Lipiello P.M., Bencherif M., Gray J.A., Peters S., Grigoryan G., Hodges H.et al. RJR-2403: a nicotinic agonist with CNS selectivity: II. In vivo characterization. J. Pharmacol. Exp. Ther. 279:1996;1422-1429.
54. Lloyd G.K., Menzaghi F., Bontempi B., Suto C., Siegel R., Akong M.et al. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 62:1998;1601-1606.
55. Luntz-Leybman V., Bickford P., Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 587:1992;130-136.
56. Marin P., Maus M., Deagher S., Glowinski J., Premont J. Nicotine protects cultured striatal neurons against N-methyl-D-aspartate receptor-mediated neurotoxicity. NeuroReport. 5:1994;1977-1980.
57. Marshall J., Schniden H. Effect of adrenaline, noradrenaline, atropine and nicotine on some types of human tremor. J. Neurol. Neurosurg. Psychiatry. 29:1966;214-218.
58. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res. 706:1996;181-193.
59. McConville B.J., Sanberg P.R., Fogelson H.M., King J., Cirino P., Parker K.W.et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol. Psychiatry. 31:1992;832-840.
60. McEvoy J.P., Freudenreich O., Levin E.D., Rose J.E. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology. 119:1995;124-126.
61. McEvoy J.P., Freudenreich O., McGee M., Vander Zwaag C., Levin E., Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol. Psychiatry. 37:1995;550-552.
62. Menzaghi F., Whelan K.T., Risbrough V.B., Rao T.S., Lloyd G.K. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J. Pharmacol. Exp. Ther. 280:1997;393-401.
63. Moll H. The treatment of postencephalitic Parkinsonism by nicotine. Br. Med. J. 1:1926;1079-1081.
64. Morens D.M., Grandinetti A., Reed D., White L.R., Ross G.W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. 45:1995;1041-1051.
65. Myrsten A., Post B., Frankenhaeuser M., Johansson G. Changes in behavioral and phsysiological activation induced by cigarette smoking in habitual smokers. Psychopharmacology (Berlin). 76:1972;232-235.
66. Nagamoto H.T., Adler L.E., Hea R.A., Griffith J.M., McRae K.A., Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol. Psychiatry. 40:1996;181-188.
67. Newhouse, P.A., Kelton, M., 1999. Clinical aspects of nicotinic agents: therapeutic applications in central nervous system disorders. In: Clementi, F., Gotti, C., Fornasari, D. (Eds.), Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors. Springer, Heidelberg, in press.
68. Newhouse P.A., Sunderland T., Tariot P.N., Blumhardt C.L., Weingartner H., Mellow A.et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology. 95:1988;171-175.
69. Newhouse P.A., Sunderland T., Narang P.K., Mellow A., Fertig J.B., Lawlor B.A.et al. Neuroendocrine, physiologic and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with Alzheimer's disease. Psychoneuroendocrinology. 15:1990;471-484.
70. Newhouse P.A., Potter A., Corwin J., Lenox R. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology. 10:1992;480-484.
71. Newhouse P.A., Potter A., Lenox R.H. Effects of nicotinic agents on human cognition: possible therapeutic applications in Alzheimer's and Parkinson's diseases. Med. Chem. Res. 2:1993;628-642.
72. Newhouse P.A., Potter A., Corwin J.et al. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology. 10:1994;93-107.
73. Newhouse P.A., Potter A., Corwin J.et al. Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease. Drug Dev. Res. 38:1996;278-289.
74. Newhouse, P.A., Singh, J., Conrath, C., Kelton M.C., 1998. The effects of nicotine in Parkinson's disease. Presented at Annual Meeting, American Psychiatric Association, New York, NY; New Research Proceedings: NR 356, 165.
75. Nordberg A. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized with PET. Acta Neurol. Scand., Suppl. 149:1993;62-65.
76. 11C -nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography Alzheimer Dis. Assoc. Disord. 9:1995;21-27.
77. Olincy A., Ross R.G., Young D.A., Roath M., Freedman R. Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology. 18:1998;175-185.
78. Owman C., Fuxe K., Jason A., Kahrstrom J. Studies of the protective actions of nicotine on neuronal and vascular functions in rats: comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber system and the effect of a dopamine agonist. Prog. Brain Res. 79:1989;267-276.
79. Perry E.K., Curtis M., Dick D.J., Candy J.M., Atack J.R., Bloxham C.A.et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 48:1985;413-421.
80. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.E., McKeth I.G.et al. Alteration in nicotinic binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
81. Perry E.K., Court J.A., Lloyd S., Johnson M., Griffiths M.H., Spurden D.et al. β-amyloidosis in normal aging and transmitter signaling in the human temporal lobe. Ann. N. Y. Acad. Sci. 777:1996;388-392.
82. Philips H.A., Shaffer I.E., Crossland K.M., Bhatia K.P., Fish D.R., Marsden C.D.et al. Autosomal dominant nocturnal frontal-lobe epilepsy: genetic heterogeneity and evidence for a second locus at 15q24. Am. J. Hum. Genet. 63:1998;1108-1116.
83. Pickworth W.B. Effects of mecamylamine on spontaneous EEG and performance in smokers and non-smokers. Pharmacol., Biochem. Behav. 56:1997;181-187.
84. Pomerleau O.F., Downey K.K., Stelson F.W., Pomerleau C.S. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J. Subst. Abuse. 7:1995;373-378.
85. Potter A., Corwin J., Lang J., Lenox R., Newhouse P.A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 improved learning in Alzheimer's disease. Psychopharmacology. 142:1999;334-342.
86. Prendergrast M.A., Jackson W.J., Terry A.V. Jr., Decker M.W., Arneric S.P., Buccafusco J.J. Central nicotine receptor agonists ABT-418, ABT-089 and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology. 136:1998;50-58.
87. Puttfarcken P.S., Manelli A.M., Arneric S.P., Donnelly-Roberts D.L. Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: studies with F11 cells. J. Neurochem. 69:1997;930-938.
88. Roberts R.G., Stevenson J.E., Westerman R.A., Pennefather J. Nicotinic acetylcholine receptors on capsaicin-sensitive nerves. NeuroReport. 6:1995;1578-1582.
89. Rose J.E., Behm F.M., Westman E.C., Levin E.D., Stein R.M., Ripka G.V. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56:1994;86-99.
90. Rose J.E., Westman E.C., Behm F.M. Nicotine/mecamylamine combination treatment for smoking cessation. Drug Dev. Res. 38:1996;243-256.
91. Sacaan A.I., Reid R.T., Santori E.M., Adams P., Correa L.D., Mahaffy L.S.et al. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist. J. Pharmacol. Exp. Ther. 280:1997;373-383.
92. Sahakian B.J., Coull J.T. Nicotine and THA: evidence for improved attention in patients with Dementia of the Alzheimer type. Drug Dev. Res. 31:1994;80-88.
93. Salomon A.R., Marcinowski K.J., Zagorski M. Nicotine inhibits amyloid formation by the β-peptide. Biochemistry. 35:1996;13568-13578.
94. Sanberg P.R., McConville B.J., Fogelson H.M., Manderscheid P.Z., Parker K.W., Blythe M.M.et al. Nicotine potentiates the effects of haloperidol in animals and patients with Tourette syndrome. Biomed. Pharmacother. 43:1989;19-23.
95. Sanberg P.R., Shytle R.D., Silver A.A. Treatment of Tourette's syndrome with mecamylamine. Lancet. 352(9129):1998;705-706.
96. Schneider J.S., Van Velson M., Menzaghi F., Lloyd G.K. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann. Neurol. 43:1998;311-317.
97. Sershen H., Hashim A., Lajtha A. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease. Pharmacol., Biochem. Behav. 28:1987;299-303.
98. Shapiro E.S., Shapiro A.K., Fulop G., Hubbard M., Mandeli J., Nordlie J.et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch. Gen. Psychiatry. 46:1989;722-730.
99. Shimohama S., Akaike A., Kimura J. Nicotine-induced protection against glutamate cytotoxicity: nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation. Ann. N. Y. Acad. Sci. 777:1996;356-361.
100. Shytle, R.D., Baker, M., Silver, A.A., Reid, B.M., Sanberg, P.R., 2000. Smoking, nicotine and movement disorders. In: Piasecki, M., Newhouse, P. (Eds.), Nicotine in Psychiatry: Emerging Trends in Psychopathology and Novel Therapeutics. American Psychiatric Press, Washington, in press.
101. Silver A.A., Sanberg P.R. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. Lancet. 342(8864):1995;182.
102. Snaedal J., Johannesson T., Jonsson J.E., Gylfadottir G. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia. 7:1996;47-52.
103. Tyas S.L. Are tobacco and alcohol use related to Alzheimer's disease? A critical assessment of the evidence and its implications. Addict. Biol. 1:1996;237-254.
104. Ulrich J., Johanson-Locher G., Seiler W.O., Stahelin H.B. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol. 94:1997;450-454.
105. Waldo M.C., Carey G., Myles-Worsley M., Cawthra E., Adler L.E., Nagamoto H.T.et al. Codistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res. 39:1991;257-268.
106. Warburton D.M., Rusted J.M. Cholinergic control of cognitive resources. Neuropsychobiology. 28:1993;43-46.
107. Warpman U., Nordberg A. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. NeuroReport. 6:1995;2419-2423.
108. Wesnes K., Warburton D. Smoking, nicotine and human performance. Pharmacol. Ther. 21:1983;189-208.
109. Wesnes K., Warburton D. Effects of scopolamine and nicotine on human performance. Psychopharmacology. 82:1985;147-150.
110. Westman, E.C., Rose, J.E., 1999. Nicotine replacement therapies and beyond. In: Piasecki, M., Newhouse, P. (Eds.), Nicotine in Psychiatry: Emerging Trends in Psychopathology and Novel Therapeutics. American Psychiatric Press, Washington, in press.
111. Whitehouse P.J., Hedreen J.C., White C.L., Price D.L.et al. Basal forebrain neurons in dementia of Parkinson's disease. Ann. Neurol. 13:1983;243-248.
112. Whitehouse P., Martino A., Antuono P., Lowenstein P.R., Cayle J.T., Price D.L.et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 371:1986;146-151.
113. 3H ] nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study Neurology. 38:1988;720-723.
114. Wilson A.L., Langley L.K., Monley J., Bauer T., Rotfunda S., McFalls E.et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory and safety. Pharmacol. Biochem. Behav. 51:1995;509-514.
115. Wolf S.S., Jones D.W., Knable M.B., Gorey J.G., Lee K.S., Hyde T.M.et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science. 273:1996;1225-1227.
116. Yamashita H., Nakamura S. Nicotine rescues PC12 cells from death induced by nerve growth factor deprivation. Neurosci. Lett. 213:1996;145-147.
117. Zamani M.R., Allen Y.S., Owen G.P., Gray J.A. Nicotinic modulates the neurotoxic effect of beta-amyloid protein (25-35) in hippocampal cultures. NeuroReport. 8:1997;513-517.